Baseline characteristics
| Characteristic . | A: IFN-γ high NIVO (n = 10) . | B: IFN-γ high NIVO + DOM BID (n = 10) . | C: IFN-γ low NIVO + DOM BID (n = 10) . | D: IFN-γ low IPI + NIVO + DOM QD (n = 10) . | D-exp: IFN-γ low IPI + NIVO + DOM BID (n = 4) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age, median (range) | 56.5 | (36–69) | 60.5 | (33–81) | 61 | (26–76) | 62 | (37–80) | 58.5 | (53–69) |
| Sex, male | 5 | (50%) | 5 | (50%) | 8 | (80%) | 8 | (80%) | 2 | (50%) |
| WHO performance status, 0 | 10 | (100%) | 10 | (100%) | 9 | (90%) | 8 | (80%) | 3 | (75%) |
| Primary tumor | ||||||||||
| Breslow thickness, median (range) | 16 | (0.1–9) | 1.3 | (0.5–4) | 2.2 | (0.8–15) | 1.2 | (0.6–2.1) | 3.0 | (0.7–3.0) |
| Ulceration | 2 | (20%) | 3 | (30%) | 4 | (40%) | 0 | (0%) | 0 | (0%) |
| Unknown primary | 1 | (10%) | 1 | (10%) | 2 | (20%) | 4 | (40%) | 1 | (25%) |
| Location lymph node metastases | ||||||||||
| Neck | 0 | (0%) | 0 | (0%) | 4 | (40%) | 1 | (10%) | 3 | (75%) |
| Axilla | 3 | (30%) | 6 | (60%) | 3 | (30%) | 5 | (50%) | 0 | (0%) |
| Inguinal/iliac region | 7 | (70%) | 4 | (40%) | 3 | (30%) | 4 | (40%) | 1 | (25%) |
| Sum target lesions on CT, median (range) | 19.5 | (15–33) | 28.5 | (15–67) | 17.5 | (15–32) | 29.5 | (16–86) | 21.5 | (18–28) |
| LDH, <ULN | 10 | (100%) | 10 | (100%) | 10 | (100%) | 10 | (100%) | 4 | (100%) |
| BRAFV600E/K positive | 4 | (40%) | 6 | (60%) | 3 | (30%) | 8 | (80%) | 3 | (75%) |
| Characteristic . | A: IFN-γ high NIVO (n = 10) . | B: IFN-γ high NIVO + DOM BID (n = 10) . | C: IFN-γ low NIVO + DOM BID (n = 10) . | D: IFN-γ low IPI + NIVO + DOM QD (n = 10) . | D-exp: IFN-γ low IPI + NIVO + DOM BID (n = 4) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age, median (range) | 56.5 | (36–69) | 60.5 | (33–81) | 61 | (26–76) | 62 | (37–80) | 58.5 | (53–69) |
| Sex, male | 5 | (50%) | 5 | (50%) | 8 | (80%) | 8 | (80%) | 2 | (50%) |
| WHO performance status, 0 | 10 | (100%) | 10 | (100%) | 9 | (90%) | 8 | (80%) | 3 | (75%) |
| Primary tumor | ||||||||||
| Breslow thickness, median (range) | 16 | (0.1–9) | 1.3 | (0.5–4) | 2.2 | (0.8–15) | 1.2 | (0.6–2.1) | 3.0 | (0.7–3.0) |
| Ulceration | 2 | (20%) | 3 | (30%) | 4 | (40%) | 0 | (0%) | 0 | (0%) |
| Unknown primary | 1 | (10%) | 1 | (10%) | 2 | (20%) | 4 | (40%) | 1 | (25%) |
| Location lymph node metastases | ||||||||||
| Neck | 0 | (0%) | 0 | (0%) | 4 | (40%) | 1 | (10%) | 3 | (75%) |
| Axilla | 3 | (30%) | 6 | (60%) | 3 | (30%) | 5 | (50%) | 0 | (0%) |
| Inguinal/iliac region | 7 | (70%) | 4 | (40%) | 3 | (30%) | 4 | (40%) | 1 | (25%) |
| Sum target lesions on CT, median (range) | 19.5 | (15–33) | 28.5 | (15–67) | 17.5 | (15–32) | 29.5 | (16–86) | 21.5 | (18–28) |
| LDH, <ULN | 10 | (100%) | 10 | (100%) | 10 | (100%) | 10 | (100%) | 4 | (100%) |
| BRAFV600E/K positive | 4 | (40%) | 6 | (60%) | 3 | (30%) | 8 | (80%) | 3 | (75%) |
Data are median (range) or n (%). DOM, domatinostat; IPI, ipilimumab; NIVO, nivolumab; ULN, upper limit of normal.